Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337623 | 0.81 | LMNA (0.39) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL3200366 | 0.80 | LMNA (0.42) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL22685010 | 0.79 | CA12 (0.46) | LMNAALDH1A1DPP4MEN1KMT2A | |
| SCHEMBL1615608 | 0.78 | LMNA (0.40) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL17652005 | 0.78 | LMNA (0.40) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL1964784 | 0.78 | LMNA (0.40) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL14361944 | 0.78 | LMNA (0.40) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL18098236 | 0.78 | LMNA (0.40) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL10675217 | 0.76 | LMNA (0.39) | LMNAALDH1A1MMP1MMP2MMP3 | |
| SCHEMBL21177575 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521396-B2 | Substituted (thioxo)carbonylaminophenyluracils | BAYER CROPSCIENCE AG (DE) | 2009-04-21 | — | — | US | claimed |
| US-20060089262-A1 | Substituted (thioxo)carbonylamino phenyl uraciles | BAYER CROPSCIENCE AG (DE) | 2006-04-27 | — | — | US | claimed |
| EP-1503994-A1 | SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES | Bayer CropScience AG (DE) | 2005-02-09 | — | — | EP | claimed |
| WO-2003093244-A1 | SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES | BAYER CROPSCIENCE AG (DE) | 2003-11-13 | — | — | WO | claimed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | claimed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-114040966-A | Method for producing insulin-producing cell using dihydroindolizinone derivative | 国立大学法人东京工业大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-111630052-A | Dihydroindazinone derivatives | 第一三共株式会社 | 2020-09-04 | — | — | CN | disclosed |
| US-7521396-B2 | Substituted (thioxo)carbonylaminophenyluracils | BAYER CROPSCIENCE AG (DE) | 2009-04-21 | — | — | US | disclosed |
| US-20060089262-A1 | Substituted (thioxo)carbonylamino phenyl uraciles | BAYER CROPSCIENCE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1503994-A1 | SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES | Bayer CropScience AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093244-A1 | SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES | BAYER CROPSCIENCE AG (DE) | 2003-11-13 | — | — | WO | disclosed |
| EP-0474561-A1 | Arylalkylamines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-03-11 | — | — | EP | disclosed |
| EP-0428434-A2 | Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089262-A1 | Substituted (thioxo)carbonylamino phenyl uraciles | NQO2, TYMP, DPYD | LMNA 4639/4885ALDH1A1 196/4885MMP1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.